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ABSTRACT Obesity, systemic inflammation, and hyperlipidemia are among the components of metabolic syndrome, a
spectrum of phenotypes that can precede the development of type 2 diabetes and cardiovascular disease. Animal studies show
that intake of anthocyanin-rich extracts can affect these phenotypes. Anthocyanins can alter the activity of tissue peroxisome
proliferator-activated receptors (PPARs), which affect energy substrate metabolism and inflammation. However, it is un-
known if physiologically relevant, anthocyanin-containing whole foods confer similar effects to concentrated, anthocyanin
extracts. The effect of anthocyanin-rich tart cherries was tested in the Zucker fatty rat model of obesity and metabolic
syndrome. For 90 days, rats were pair-fed a higher fat diet supplemented with either 1% (wt=wt) freeze-dried, whole tart
cherry powder or with a calorie- and macronutrient-matched control diet. Tart cherry intake was associated with reduced
hyperlipidemia, percentage fat mass, abdominal fat (retroperitoneal) weight, retroperitoneal interleukin-6 (IL-6) and tumor
necrosis factor-a (TNF-a) expression, and plasma IL-6 and TNF-a. Tart cherry diet also increased retroperitoneal fat PPAR-a
and PPAR-g mRNA (P¼ .12), decreased IL-6 and TNF-a mRNA, and decreased nuclear factor kB activity. In conclusion, in
at-risk obese rats fed a high fat diet, physiologically relevant tart cherry consumption reduced several phenotypes of metabolic
syndrome and reduced both systemic and local inflammation. Tart cherries may reduce the degree or trajectory of metabolic
syndrome, thereby reducing risk for the development of type 2 diabetes and heart disease.
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receptor
INTRODUCTION
Obesity, hyperlipidemia, and systemic inflammationare among several clinical parameters of prediabetes of
‘‘metabolic syndrome,’’ and these phenotypes are positively
correlated with the incidence of type 2 diabetes and cardio-
vascular disease.1 Fruit and vegetable intake is inversely
correlated with cardiovascular morbidity and mortality.2–4
Furthermore, fruits and vegetables contain non-nutritive
phytochemicals that may contribute to their health-promoting
effects.
Anthocyanins are a major subclass of phytochemical
flavonoids that are principally found in red-, blue-, and
purple-pigmented fruits and vegetables. Several studies
have suggested that anthocyanin-rich botanical extracts can
modify lipid metabolism in vitro and can reduce hyperlip-
idemia in vivo.5–10 Reductionistic approaches using in vitro
approaches and=or isolated phytochemicals can attempt to
reveal mechanisms of effect. For example, isolated antho-
cyanins and anthocyanin-rich extracts have been shown to
modify the activity of the peroxisome proliferator-activated
receptor (PPAR).11,12 PPAR is a transcription factor that
controls genes related to metabolism and inflammation, and
PPAR agonist drugs are currently prescribed to reduce risk
and=or manage type 2 diabetes.13–15 Tart cherries (Prunus
cerasus) are a rich edible fruit source of anthocyanins.16,17
In lean rats, we previously demonstrated that inclusion of
whole tart cherry powder (1% wt=wt) into a low fat diet
significantly reduced total cholesterol and triglycerides, re-
duced fatty liver, and increased liver PPAR isoform
mRNA.18 However, it is uncertain what disease phenotypes
would be lost, sustained, or amplified if studied in an obesity-
prone model fed a higher fat diet. This model is increasingly
relevant to our growing at-risk population with metabolic
syndrome and to typical patterns of human diets, which in-
clude elevated saturated fat and cholesterol.
Zucker fatty rats develop obesity, hyperlipidemia, insulin
resistance, and systemic inflammation. Importantly, Zucker
fatty rats are responsive to and benefited by PPAR agonist
drugs.19–22 We then tested the effect of 90-day diet provi-
sion of a high fat diet containing whole tart cherry powder.
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We measured blood lipids, systemic inflammation as
measured by plasma tumor necrosis factor-a (TNF-a) and
interleukin-6 (IL-6), and percentage fat mass. Because
abdominal adipose tissue is a significant source of pro-
inflammatory cytokines, we surveyed mRNA related to in-
flammation in the abdominal retroperitoneal fat pad. We
also measured abdominal fat levels of IL-6 and TNF-a and




Male Zucker fatty rats (6 weeks old) were acquired from
Harlan (Indianapolis, IN, USA) and were housed two per
cage. Rats were housed on 12-hour light:dark cycles. At
7 weeks of age, rats were randomized to two groups (n¼ 12
each): 1% tart cherry powder by weight and 0.85% addi-
tional carbohydrate (dextrose:fructose 1:1) by weight to
control for the additional carbohydrate provided by the tart
cherry powder. Tart cherry powder or the dextrose:fructose
mixture was incorporated into powdered higher fat diet as
described in Table 1 (diet number 102121, Dyets, Bethle-
hem, PA, USA). The cherry product was a freeze-dried
powder from individually quick-frozen tart cherries, har-
vested in northern Michigan and prepared by VanDrunen
Farms (Momence, IL, USA). Tart cherry powder nutrient
analysis was conducted by VanDrunen Farms and its sub-
sidiary Futureceuticals (Momence), and further anthocy-
anin analysis was conducted by our group using liquid
chromatography-mass spectrometry (Table 2). Diets were
mixed weekly, vacuum-sealed, and stored at 48C. Rats were
provided 20 g of diet per head=day; this was approximately
10% below ad libitum intake to ensure complete consump-
tion and equal food intake among all rats in the study. Water
was provided ad libitum. This protocol was approved by the
University of Michigan’s University Committee on the Use
and Care of Animals.
Liquid chromatography-mass spectrometry
analysis of tart cherry powder
Individually quick-frozen tart cherry powder (1 g) was
extracted with 10 mL of methanol=water=acetic acid
(85:15:0.5 by volume) in a 15-mL screw-cap tube and
shaken overnight in the dark at 48C. The sample was vortex-
mixed and then sonicated for 10 minutes at 258C and filtered
(pore size, 0.45 mm). An Alliance 2695 HPLC (Waters,
Milford, MA, USA) was used to generate a binary gradient
with 0.05% trifluoroacetic acid in water as the aqueous
solvent (solvent A) and 0.05% trifluoroacetic acid in ace-
tonitrile as the organic modifier (solvent B). Chromato-
graphic separation was achieved with a Gemini 5-mm
(particle size) C18 150-2.00-mm (Phenomenex, Torrance,
CA, USA) reverse-phase column held at 358C using a flow
rate of 0.19 mL=minute. The column was initially equili-
brated to 8% solvent B, increased to 18% solvent B over 10
minutes, 28% solvent B over the next 8 minutes, 40% sol-
vent B in 1 minute, 60% solvent B in 3 minutes, and then
returned to initial conditions. The sample chamber was
cooled to 108C, and the injection volume was 10mL. Ef-
fluent from the high-performance liquid chromatography
column was directed into the electrospray ionization probe
Table 2. Tart Cherry Powder Anthocyanin Profile as Measured by Liquid Chromatography (LC)-Mass Spectrometry (MS)
Anthocyanin LC retention time MS=MS (m=z) mg=g of dry weight
Cyanidin 3-sophoroside 12.668 611? 287 0.0041
Cyanidin 3-glucosylrutinoside 13.618 757? 611, 287 0.3757
Cyanidin 3-glucoside 14.416 449? 287 0.0071
Cyanidin 3-rutinoside 15.096 595? 287 0.2261
Peonidin 3-glucoside 17.333 463? 301 0.0388
Pelargonidin 16.959 271? 121 0.0086
Table 1. Profiles of the Tart Cherry-Supplemented




Total protein 20.0 20.0
Total carbohydrate 33.0 33.0
Total fat 47.0 47.0
kCal=g of diet 3.9 3.9
g=kg of diet
Casein 200 200








Fiber from cherry 0.9 0
Corn oil 25 25
Cholesterol 860 ppm 860 ppm
Stripped lard 178 178
Choline bitartrate 2 2
Vitamin Mix #300050 10 10
Mineral Mix #200000 35 35
Vitamin C 0.002 0
Vitamin A 441.4 IU 0




Base diet is Dyet number 102121 from Dyets, Inc. IU, international units;
RE, retinol equivalence.
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of a TSQ Quantum Ultra AM triple quadrupole mass spec-
trometer (ThermoFinnigan, San Jose, CA, USA). Positive
ions were generated with the following parameters: spray
voltage, 3,000 V; sheath gas, 40 arbitrary units; auxiliary
gas, 10 arbitrary units; and capillary temperature, 2508C.
Tube lens voltages were optimized for each compound. Data
were collected in centroid mode. Single reaction monitoring
was used for mass analysis and quantification, with au-
thentic standards for verification. Data analysis was per-
formed with Xcalibur quantitation software (version 1.4
SR1, ThermoFinnigan).
Dual X-ray absorptiometry (DEXA)
Lean body mass and fat mass were measured every
4 weeks using DEXA on an Eclipse Peripheral Dexa Scanner
with pDEXA Sabre software version 3.9.4 (Norland Medi-
cal Systems, Fort Atkinson, WI, USA) in research mode.
Rats were anesthetized with 4% isoflurane and maintained
with 1% isoflurane. After calibration, each rat was placed
on the platform and scanned from nose to anus at 30 mm=
second with a resolution of 1.01.0 mm. Results for per-
centage fat mass and lean body mass were determined rel-
ative to body weight on the day of the scan.
Sample collection
After 90 days of feeding, rats were fasted for 18 hours and
sacrificed by decapitation. Trunk blood was collected in
0.6-mL capacity serum-separator tubes, allowed to clot at
room temperature, and spun at 5,000 g for 7 minutes at 48C.
Serum was aliquoted and stored at 808C until further
analysis. A further fraction of truck blood was collected in a
7-mL EDTA-containing Vacutainer (Becton Dickinson,
Franklin Lakes, NJ, USA) and spun at 48C at 1,500 g.
Plasma was then aliquoted and stored at 808C until further
analysis. Tissues were harvested and weighed, including
heart, liver, kidneys, epididymal fat, and retroperitoneal fat.
Tissues were snap-frozen in liquid nitrogen and stored at
808C until further analysis.
Serum and plasma analysis
Serum lipids and glucose were measured using the auto-
mated IDEXX VetTest Chemistry Analyzer from IDEXX
Laboratories (Westbrook, ME, USA). Plasma TNF-a and
IL-6 were measured by immunoassay (R&D Systems,
Minneapolis, MN, USA) according to the manufacturer’s
instructions.23
Tissue inflammation
A fragment of frozen retroperitoneal fat was powdered
and homogenized with T-Per Solution (Pierce, Rockford,
IL, USA) mixed with Complete Protease Inhibitor Mini-Tab
cocktail (Roche, Indianapolis, IN, USA), according to the
manufacturer’s protocol. Levels of TNF-a and IL-6 were
measured by enzyme-linked immunosorbent assay follow-
ing the manufacturer’s protocols (Quantikine, R&D Sys-
tems). Both experimental samples and cytokine standards
were assayed in duplicate, and the level of TNF-a and IL-6
was calculated from the standard curve and expressed as the
average pg of TNF-a and IL-6 per mg of total protein.
Protein concentrations were determined using a BCA Pro-
tein Assay kit (Pierce).
Real-time reverse transcription polymerase
chain reaction (PCR)
Total RNA from frozen fragments of retroperitoneal fat
was isolated with RNeasy Lipid Tissue Midi Kit (Qiagen,
Valencia, CA, USA) following the manufacturer’s protocol.
Samples (n¼ 4 per group) were analyzed by real time-PCR
using a custom RT2 Profiler PCR Array and its proprietary
reagents (SABiosciences, Frederick, MD, USA). First,
cDNA was prepared using the RT2 First Strand Kit. cDNA
was then added to the RT2 qPCR Master Mix, which con-
tains SYBR Green and a reference dye. The mixture is then
added to a provided 96-well plate, which has 48 replicate
wells containing preoptimized, species-specific primer sets
for controls (housekeeping genes, genomic DNA control,
reverse transcription control, and positive PCR control) and
the experimental genes of interest (PPAR-a, PPAR-g,
NFkB, IKBa, IL-6, and TNF-a). Each primer set of the array
has undergone quality assurance=quality control analysis by
real-time reverse transcription PCR and gel electrophoresis
to confirm the generation a single gene product, with no
additional peak and=or bands that would indicate primer
dimer formation. Relative expression of PPAR-a, PPAR-g,
NFkB, IKBa, IL-6, and TNF-a was determined by the DDCt
method as described by Livak and Schmittgen.24 DCt for
each gene (averaged across four animals per group) was
calculated relative to the average of five housekeeping genes
(P1 large ribosomal protein, hypoxanthine guanine phos-
phoribosyl transferase, ribosomal protein L13A, lactate
dehydrogenase A, and b-actin). DDCT was then determined
as DCt (group 2, cherry) minus DCt (group 1, control), and
the values were then back-transformed (2DDCt) to calculate
the fold change of each transcript.
Tissue NFkB activity
A fragment of frozen retroperitoneal fat was subjected to
subcellular fractionation (n¼ 6 per group) using the tech-
nique of Kutoh et al.25 NFkB activity was measured in both
nuclear and cytosolic extracts using the high-throughput
TransAM enzyme-linked immunosorbent assay (Active
Motif, Carlsbad, CA, USA). The TransAM kit contains a 96-
well plate coated with immobilized oligonucleotide that
contains the NFkB consensus site (50-GGGACTTTCC-30).
The active form of NFkB contained in the cell fractions then
binds to the oligonucleotide. The provided primary antibody
recognizes an epitope on the NFkB subunit p65 that is only
accessible when NFkB is activated and bound to kB con-
sensus sites. A horseradish peroxidase-conjugated second-
ary antibody provides colorimetric detection of the bound
complex at 450 nm. NFkB activity requires nuclear trans-
location, so the simultaneous assessment of NFkB activity
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in the cytosolic fraction served as a control for successful
cell fractionation.
Statistical methods
Transcript differences are determined asSD using the
DDCt method as described by Livak and Schmittgen,24 using
the PCR Array data analysis web portal of SABiosciences
(http:==www.sabiosciences.com=pcr=arrayanalysis.php). All
other experimental values are expressed as SEM and
compared using a two-tailed Student’s t test. For all mea-
sures, a value of P< .05 was considered statistically sig-
nificant.
RESULTS
Fasting glucose, insulin, total cholesterol, and triglyceride
were significantly reduced in the tart cherry-fed animals.
Plasma IL-6 and TNF-a were reduced by 44% and 40%,
respectively (Table 3). Despite pair-feeding and matched
caloric intake, tart cherry intake was associated with a lower
body weight (Table 4). This difference was not significant
until week 8 of the 12-week study. DEXA scan results in-
dicated that by week 12, tart cherry reduced relative fat mass
(18%, P< .05) and increased lean body mass (þ14%,
P< .05). These treatment results were apparent after week 4
(Table 4).
Tart cherry was associated with a nonsignificant increase
in terminal heart and kidney weight but a statistically sig-
nificant increase in liver weight (Table 5). These effects are
also observed in rats given PPAR agonist drugs, which
causes proliferation of cellular peroxisomes and increased
organ weight.26–29 Retroperitoneal fat pad weight was re-
duced (17%, P< .05), whereas the combined epididymal
fat plus perirenal fat pad weight was not significantly af-
fected by cherry (Table 5).
We further explored treatment effect on the retroperito-
neal fat pad. Tart cherry diet significantly reduced retro-
peritoneal fat expression of TNF-a (3.2-fold reduction,
P< .01) and IL-6 (3.6-fold reduction, P< .01) (Fig. 1).
Gene expression in retroperitoneal fat was also altered by
cherry. PPAR-a mRNA is significantly increased (3.4-fold,
P¼ .014) by tart cherry diet. PPAR-g mRNA was also in-
creased (2.7-fold), and this change approached statistical
significance (P¼ .122). Both NFkB and its activation in-
hibitor IKBa are reduced by cherry. IKBa transcription is
regulated by PPARs, and reduced adipose tissue expression
and activity of IKBa could reduce NFkB-related inflam-
mation. In fact, several NFkB-regulated transcripts are ex-
pectedly reduced in retroperitoneal fat by tart cherry,
including TNF-a (2.9-fold, P¼ .006) and IL-6 (4.5-fold,
P¼ .013) (Table 6). Finally, NFkB activity in nuclear ex-
tracts of retroperitoneal fat was significantly reduced by
cherry (Fig. 2).
Table 3. Serum and Plasma Measures in Rats Fed
Tart Cherry-Supplemented (CHE) Diet
and Carbohydrate-Supplemented Control (CON) Diet
CON CHE
Total cholesterol (mg=dL) 207 14 185 15*
Total triglycerides (mg=dL) 284 23 241 18*
Glucose (mg=dL) 139 8 117 7*
Insulin (pg=mL) 8.9 0.5 7.1 0.5*
IL-6 (pg=mL) 289 31 191 22*
TNF-a (pg=mL) 43 5 26 4*
Data are mean SEM values (n¼ 12 per group). *P< .05, versus CON.
Table 4. Serial Body Weight and DEXA Measures
in Rats Fed Tart Cherry-Supplemented (CHE) Diet
and Carbohydrate-Supplemented Control (CON) Diet
Week 0 Week 4 Week 8 Week 12
Body weight
CON 188 9 334 17 445 17 517 25
CHE 191 6 343 19 433 22 486 32*
% lean body mass
CON 58 4 44 2 33 2 26 2
CHE 55 3 47 3 38 3* 34 2*
% fat mass
CON 29 3 44 2 55 3 63 3
CHE 33 2 41 3 48 3* 54 4*
Data are meanSEM values (n¼ 6 per group). *P< .05, versus time-
matched CON.
Table 5. Terminal Organ and Tissue Weights Expressed
Relative to Tibial Length in Rats Fed Tart
Cherry-Supplemented (CHE) Diet
and Carbohydrate-Supplemented Control (CON) Diet
g=tibial length (cm)
CON CHE
Heart weight 0.29 0.04 0.35 0.04
Liver weight 6.8 0.3 8.5 0.4*
Kidney weight 0.9 0.1 1.1 0.1
Retroperitoneal fat pad weight 6.4 0.3 5.3 0.2*
Epididymalþ perirenal fat pad weight 3.9 0.2 4.1 0.3
Data are meanSEM values (n¼ 12 per group). *P< .01, versus CON.
FIG. 1. Retroperitoneal fat IL-6 and TNF-a expression in rats fed
tart cherry-supplemented (CHE) diet and carbohydrate-supplemented
control (CON) diet. Data are mean SEM values (n¼ 6 per group).
*P< .05 versus CON.
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DISCUSSION
Excessive fat accumulation in adipose tissue, liver, and
other organs precipitates the development of metabolic
changes that increase overall risk for morbidity. Abnorm-
alities that often accompany obesity include hypertension,
impaired glucose tolerance, insulin resistance, hyperinsu-
linemia, and dyslipidemia. Visceral obesity, which is char-
acterized by excess fat storage in and around the abdomen,
is the prime cause of the metabolic abnormalities and there-
fore represents an important target in the treatment of met-
abolic syndrome. Adipose tissue is now clearly understood
to be an endocrine organ and a major site of chronic low-
grade inflammation that is associated with obesity. Adipose
tissue-derived cytokines and ‘‘adipokines’’ play important
roles in energy homeostasis, local and systemic energy in-
flammation, and insulin resistance. Specifically, abdominal
fat is a primary source of adipokines and is therefore as-
sociated with greater pathologic consequence compared to
other fat depots.
Within white adipose tissue, TNF-a is expressed in adi-
pocytes, stromovascular cells, and macrophages. However,
TNF-a produced by the adipocytes has only a local effect
because it cannot be secreted; it is macrophage-produced
TNF-a that is secreted and thus contributes to plasma
TNF-a.30 The expression of TNF-a in white adipose tissue
correlates with obesity and insulin resistance.31 Besides its
role in white adipose tissue, TNF-a increases the expression
of genes involved in the de novo synthesis of fatty acids and
decreases mRNA transcripts involved in fatty acid oxidation
in liver. TNF-a also regulates the expression of other adi-
pokines in white adipose tissue, such as IL-6. Approxi-
mately one-third of plasma IL-6 is produced by adipocytes,
and IL-6 synthesis and secretion are approximately three
times greater in visceral fat compared to subcutaneous fat.32
The plasma levels of IL-6 positively correlate with fat mass,
obesity, impaired glucose tolerance, and insulin resistance
and thus could be used to predict the development of type 2
diabetes and cardiovascular disease.32,33 IL-6, like TNF-a,
modulates the insulin sensitivity of the liver and of skeletal
muscle, thereby supporting the notion that cytokines pro-
duced by the adipose tissue influence whole-body insulin
sensitivity.
Anthocyanins and PPAR activation
The ligand-activated transcription factors of the PPAR
family are involved in the regulation of inflammation and
energy homeostasis and represent important targets for
obesity, obesity-induced inflammation, and metabolic syn-
drome. The PPAR isoforms (a, g, and d) share a common
mode of action that involves heterodimerization with the
nuclear receptor retinoid X receptor and subsequent binding
to specific PPAR-responsive elements in the promoter re-
gion of target genes.
In abdominal fat, we observed here that cherry intake
reduced inflammation and reduced expression of inflam-
mation-related genes. This effect may be related to bio-
available tart cherry anthocyanin effects on adipose PPARs.
Current results show that the cherry-enriched diet was as-
sociated with enhanced PPAR isoform mRNA in retroper-
itoneal fat. The effect of tart cherry on PPAR isoforms is
supported by previous findings with concentrated anthocy-
anins or anthocyanin-rich botanical extracts. Munoz-Espada
and Watkins11 showed in prostate cancer cells that cyanidin
increases PPAR-g expression. Xia et al.12 showed that
isolated anthocyanins induced cholesterol efflux from mac-
rophages in a PPAR-g-dependent manner and that antho-
cyanins increased both PPAR-g expression and PPAR-g
transcriptional activity in a dose-dependent fashion. Park
et al.9 showed in diabetic mice that diets enriched with
anthocyanin-rich mulberry leaf extract reduced glucose,
insulin, and triglyceride while increasing liver and fat tissue
expression of PPAR-g, PPAR-a, and liver lipoprotein lipase.
In the current study, tart cherry diet was associated with
significantly increased abdominal fat PPAR-a mRNA ex-
pression. PPAR-a affects multiple target genes involved in
lipid metabolism and inflammation. We previously dem-
onstrated in lean animals fed a low fat diet that tart cherry
intake was associated with increased liver PPAR-a mRNA,
reduced liver neutral lipid fat content, enhanced hepatic
acyl-coenzyme A oxidase activity, and reduced fatty acid
synthase activity.18 In the current model, the effect of tart
cherry intake on reduced body weight, total fat mass,
hyperlipidemia, abdominal fat mass, and inflammation may
be derived from one of more of these PPAR-a-related
mechanisms. PPAR-a agonists have a clear anorexic effect
resulting in decreased food intake,34 but the pair-feeding
Table 6. PCR Array Data in Expressed in Fold Change
in mRNA in Retroperitoneal Fat in Rats Fed Tart
Cherry Diet, Relative to Control Diet







Data are mean values (n¼ 4 per group).
FIG. 2. Retroperitoneal fat NFkB activity in nuclear and cytosolic
extracts from rats fed tart cherry-supplemented (CHE) diet and car-
bohydrate-supplemented control (CON) diet. Data are mean SEM
values (n¼ 6 per group). *P< .05 versus CON.
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paradigm used here effectively eliminates that parameter
from the possible mechanisms of effect. The mechanisms
of PPAR effect on inflammation is likely multifaceted.
PPAR-a activation reduces adipocyte size,35 and smaller
adipocytes secrete less inflammatory cytokines versus larger
adipocytes. PPAR-a activation also enhances the transcrip-
tion of an inhibitor of pro-inflammatory NFkB, IKBa, a
PPAR-regulated transcript that limits the nuclear translo-
cation and subsequent activation of NFkB. Additionally,
PPAR activation may result in systemic events likely orig-
inating from liver, such as altered hepatic production of pro-
inflammatory acute-phase proteins.
In the current study, tart cherry diet was also associated
with increased abdominal fat PPAR-g mRNA expression.
Although the degree of change approached statistical sig-
nificance (P¼ .122), the difference may still carry biological
significance. We previously demonstrated in lean animals
fed a low fat diet that tart cherry intake increased liver
PPAR-g mRNA.18 PPAR-g regulates genes important for
adipogenesis, lipid metabolism, and glucose control.36–42
Because we observed reduced rather than enhanced fat
mass, the lipid oxidation-promoting effects of PPAR-a
agonism appear to have overcome the effects of PPAR-g
agonism on lipid balance. Similar to PPAR-a, PPAR-g is
involved in governing the inflammatory response. Inflam-
matory adipokines mainly originate from macrophages
residing within adipose tissue. PPAR-g agonists can alter
macrophage phenotype from ‘‘classically activated,’’ pro-
inflammatory macrophages to the ‘‘alternatively activated,’’
anti-inflammatory phenotype,43 and PPAR-g agonists may
also induce macrophage-specific cell death.44 Finally,
PPAR-g activation could alter downstream NFkB activity
and the resulting pro-inflammatory genes, as is found with
PPAR-a activation.
In correlation with effects on PPARs, cherry diet was
associated with reduced retroperitoneal fat nuclear NFkB.
Because NFkB is a vital regulator of inflammation, in-
cluding the expression of TNF-a and IL-6, the diet effect on
NFkB may be responsible for the reduced expression of
tissue TNF-a and IL-6 observed here (as shown in Fig. 1).
However, we cannot rule out the involvement of addi-
tional transcription factors in this effect, such as activator
protein 1. As TNF-a and IL-6 are regulated by multiple
transcription factors, a broader assessment of transcription
factor activation in the fat tissue is warranted. Also, because
whole fragments of adipose tissue were analyzed, it is un-
certain which cell types within the retroperitoneal fat were
most affected. For example, cherry diet could have affected
NFkB activity in adipocytes, resident macrophages, and=or
endothelial cells. However, the collective result is clear—
the addition of tart cherry reduced inflammation in retro-
peritoneal fat. The determination of affected cell subtypes
requires further investigation.
Results in context
The current study uses an anthocyanin-rich whole food.
However, the results may be impacted by the complex
polypharmacy of diverse bioavailable cherry phytochemi-
cals and by their varied sugar moieties, which affect ab-
sorption, distribution, metabolism, and excretion. Available
literature is sparse when specifically relating whole foods
containing anthocyanins to the phenotypes of obesity, hy-
perlipidemia, insulin resistance, glucose tolerance, and in-
flammation. We previously reported that intake of tart
cherry (1% wt=wt of diet) significantly reduced fasting
glucose, insulin, total cholesterol, and triglyceride in the
lean Dahl-salt sensitive rat model.18 Prior et al.45 examined
the effect of anthocyanin-rich whole blueberry and straw-
berry consumption on dietary fat-induced obesity. Mice
were fed a diet containing 10%, 45%, or 60% kilocalories
from fat, with or without freeze-dried whole berry pow-
ders at 10% (wt=wt) of diet. Animals were fed ad libitum,
and after 80 days, blueberry-fed mice had 14% higher
body weight, 27% higher percentage body fat, and 32%
higher perigonadal (epididymal) fat weight than controls.
Strawberry-fed mice had 1% higher body weight and 11%
higher percentage body fat but no change in epididymal
fat weight versus control. However, parallel studies using
matched content of their respective isolated berry anthocy-
anins showed reduced body weight and reduced percentage
body fat. This difference between whole fruit and extract
was evident despite the matched carbohydrate-derived cal-
ories and total calorie content per gram between diets. The
difference between in vivo effects of the whole berry and
isolated anthocyanins is unknown. The specific profile of
sugars present in the whole foods and the presence of other
phytochemicals may alter bioavailability and in vivo ef-
fects. In addition, a pair-feeding approach, as we used in the
current study, may be required to eliminate the confounder
of food intake. For example, whole blueberry-fed rats ate
roughly 12% more calories per day than control rats. Given
the length of the study, this may have contributed to weight
gain or adiposity. However, the whole strawberry diet in-
creased percentage body fat in the absence of greater aver-
age daily food intake, showing further diverging effects
between the fruits. Indeed, the bioavailability and in vivo
effects of anthocyanin-containing fruits are not universal,
which requires detailed comparative studies like those of
Prior et al.45 and Joseph and co-workers.46,47
Studies with anthocyanin-rich extracts tend to support our
current results. Tsuda et al.48 showed that in high-fat fed
mice, an anthocyanin-rich extract from purple corn signifi-
cantly reduced fat mass, hyperlipidemia, hyperinsulinemia,
and blood glucose. The anthocyanin extract-enriched diet
also significantly reduced tissue lipid accumulation and the
activity of enzymes that promote fat storage. Xia et al.8,49
showed in atherosclerosis-prone mice that diets supple-
mented with an anthocyanin-rich extract from black rice
significantly reduced atherosclerosis, total cholesterol, tri-
glyceride, and tissue cholesterol and increased high-density
lipoproteins. Jayaprakasam et al.50 conducted a study in
mice using Cornelian ‘‘cherry.’’ This is not a true cherry of
the agriculturally employed Prunus species, but is rather the
red fruit of an ornamental dogwood tree (Cornus mas).
These researchers reported that C57Bl=6 mice ingesting
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Cornelian cherry-derived anthocyanin extract with a high-
fat diet showed a significant decrease in weight gain and
hepatic lipid accumulation while maintaining blood glucose
control. Our findings in a whole-food model reflect those
obtained with anthocyanin-rich botanical extracts. How-
ever, we cannot exclude the benefits of other tart cherry-
derived phytochemicals, including quercetin, melatonin,
isorhamnetin, and kaempferol. These compounds may exert
independent or synergistic effects towards our observed
phenotypes.
In summary, tart cherry-enriched diets were associated
with significantly reduced body weight, abdominal fat, re-
duced blood lipids, reduced plasma inflammation, and re-
duced fasting glucose. In addition, tart cherry intake was
associated with increased expression of PPAR isoforms and
PPAR-related genes in abdominal fat, reduced abdominal
fat IL-6 and TNF-a, and reduced NFkB activity. Future
studies will histologically examine the abdominal fat for the
effect of tart cherry on macrophage presence and on the size
and number of adipocytes; these parameters affect the levels
of both local and systemic adipokines. As a rich whole-food
source of anthocyanins, tart cherry-enriched diets may
modify several key risk indicators for type 2 diabetes. Fur-
ther studies are needed in human subjects with metabolic
syndrome to ascertain the degree and spectrum of tart-cherry
derived clinical benefits.
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